The Company

Eurocine Vaccines has attracted internationally recognized experts to quest for the vaccines of tomorrow. Specialized in vaccine development, and with decades long experience, the highly qualified team has a proven record to manage all aspects of vaccine development including preclinical and clinical development, scalability into production, as well as business development and financing.

Today a publicly listed company situated close to the Karolinska Institutet, home of the Nobel Assembly.​

Read our story =>
Get to know our candidates =>
Learn more how we bridge the gap between innovation and market =>
For investors =>



CEO and Board Director

Dr. Hans Arwidsson

Dr. Hans Arwidsson is a former Air Force pilot with more than three decades of broad cross-functional executive experience from the pharmaceutical industry. Both from Big Pharma as AstraZeneca, and from several independent entrepreneurial companies, before joining Eurocine Vaccines. He holds a M.Sc. and a Ph.D. in pharmaceutical sciences from Uppsala University as well as an Executive MBA from Stockholm School of Economics.

Director of Preclinical Development

Dr. Karl Ljungberg

Dr. Karl Ljungberg runs an art museum together with his family and has extensive experience of immunology, virology and particularly vaccinology from Karolinska Institutet, University of North Carolina and Public Health Agency of Sweden. He holds a M.Sc. in Molecular Biology from Stockholm University and a Ph.D. in Infectious Disease Control from Karolinska Institutet.

Project Leader CMC Development

Dr. Stephen Toddo

Dr. Stephen Toddo’s curiosity for biology begun with a passion for training and interest in the human body. After leaving his career as a Personal Trainer he graduated in neurochemistry, with specialization on molecular neurobiology followed by a Ph.D. where he specialized in protein production, focusing in expression of difficult-to-express proteins. Prior joining Eurocine Vaccines he worked with development of manufacturing procedures and purification processes at SOBI.


Chairman of the Board

Dr. Pierre A. Morgon

Today, Dr Morgon is a well acknowledged name with over 30 years of experience in the global pharmaceutical and biological industry. He has previously served at senior positions at e.g. ICI-Pharma, Synthelabo, Yamanouchi Pharma, BMS, Drug Abuse Sciences, Bio Alliance Pharma , Schering-Plough and Aventis Sanofi Pasteur. Today, a CEO, Chairman, Non-Executive Director and Advisor for a multitude of companies within the vaccine industry, as well as Regional Partner of Merieux Develeppement. Pierre A. Morgon holds a Doctorate of Pharmacy, a Master in Business Law and a MBA.

Non-Executive Director of the Board

Dr. Bengt Gustavsson

Dr. Bengt Gustavsson has held several leading positions in life science, both in large organizations such as Novartis and Sanofi-Aventis, and in smaller companies, e.g. Oncopeptides AB, and is now a consultant in medical affairs and clinical research. Bengt Gustavsson has been a non-executive board director in Nanexa AB and WntResearch AB. He holds a M.Sc. in pharmaceutical sciences and a Ph.D. in medical sciences, both from Uppsala University.

Non-Executive Director of the Board

Mr. Pär Thuresson

With a proven record as entrepreneur and businessman, Mr Thuresson is today the CEO and Board Director of the Industry Group Thuresson Sweden AB and a non-executive Director in several other companies.

President, CEO and Board Director

Dr. Hans Arwidsson

Please see Team above.